Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) gapped down prior to trading on Monday . The stock had previously closed at $1.25, but opened at $1.21. Sunesis Pharmaceuticals shares last traded at $1.21, with a volume of 100 shares trading hands.

A number of research firms have recently commented on SNSS. Oppenheimer restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research note on Wednesday, August 12th. Zacks Investment Research lowered Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, July 30th. Finally, ValuEngine cut shares of Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, September 3rd. Six equities research analysts have rated the stock with a hold rating, The stock currently has a consensus rating of “Hold” and an average price target of $6.67.

The firm has a fifty day simple moving average of $2.58 and a 200-day simple moving average of $4.09. The firm has a market cap of $26.60 million, a price-to-earnings ratio of -0.67 and a beta of 1.74.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its quarterly earnings data on Tuesday, August 11th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.60). On average, research analysts anticipate that Sunesis Pharmaceuticals, Inc. will post -1.5 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Corriente Advisors LLC acquired a new stake in Sunesis Pharmaceuticals during the first quarter worth approximately $1,254,000. Avidity Partners Management LP increased its holdings in Sunesis Pharmaceuticals by 207.9% in the 1st quarter. Avidity Partners Management LP now owns 4,310,000 shares of the biopharmaceutical company’s stock valued at $1,788,000 after buying an additional 2,910,000 shares during the period. BlackRock Inc. increased its holdings in Sunesis Pharmaceuticals by 96.9% in the 1st quarter. BlackRock Inc. now owns 2,290,180 shares of the biopharmaceutical company’s stock valued at $950,000 after buying an additional 1,127,038 shares during the period. Jane Street Group LLC bought a new position in Sunesis Pharmaceuticals in the 2nd quarter valued at about $36,000. Finally, Burrage Capital Management LLC increased its holdings in Sunesis Pharmaceuticals by 24.5% in the 1st quarter. Burrage Capital Management LLC now owns 682,586 shares of the biopharmaceutical company’s stock valued at $280,000 after buying an additional 134,358 shares during the period. Institutional investors and hedge funds own 20.89% of the company’s stock.

About Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

See Also: What is intrinsic value?

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.